Evidence map›Paper›PMID 26071243›Full record

ArticleJournal of biomolecular screening2015

Positive Modulation of the Glycine Receptor by Means of Glycine Receptor-Binding Aptamers.

Nancy Dekki Shalaly, Eduardo Aneiros, Michael Blank, Johan Mueller, Eva Nyman, Michael Blind, Michael A Dabrowski, Christin V Andersson, Kristian Sandberg

Open access · hybridAbstract read
In one paragraph

Article in Journal of biomolecular screening, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Nancy Dekki ShalalyDepartment of Neuroscience, AstraZeneca R&D, Södertälje, Sweden and Division of Protein Technology, School of Biotechnology, Royal Institute of Technology, Stockholm, Sweden ndekki@hotmail.com.
Eduardo AneirosDepartment of Neuroscience, AstraZeneca R&D, Södertälje, Sweden and Lead Discovery Technologies, Merck Serono SA, Geneva, Switzerland.
Michael BlankAptaIT GmbH, Goethestrasse 52, Munich, Germany.
Johan MuellerDepartment of Structural Chemistry Laboratory, AstraZeneca R&D, Mölndal, Sweden.
Eva NymanDepartment of Neuroscience, AstraZeneca R&D, Södertälje, Sweden.
Michael BlindAptaIT GmbH, Goethestrasse 52, Munich, Germany.
Michael A DabrowskiPelago Bioscience, Nobels väg 3, Solna, Sweden.
Christin V AnderssonDepartment of Neuroscience, AstraZeneca R&D, Södertälje, Sweden.
Kristian SandbergDepartment of Translational Science, Respiratory, AstraZeneca R&D, Mölndal, Sweden and Department of Medicinal Chemistry, Science for Life Laboratory, Biomedical Center, Uppsala University, Uppsala, Sweden.
AstraZeneca (Sweden) · SEKTH Royal Institute of Technology · SEPelago Bioscience (Sweden) · SEUppsala University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

According to the gate control theory of pain, the glycine receptors (GlyRs) are putative targets for development of therapeutic analgesics. A possible approach for novel analgesics is to develop a positive modulator of the glycine-activated Cl(-) channels. Unfortunately, there has been limited success in developing drug-like small molecules to study the impact of agonists or positive modulators on GlyRs. Eight RNA aptamers with low nanomolar affinity to GlyRα1 were generated, and their pharmacological properties analyzed. Cytochemistry using fluorescein-labeled aptamers demonstrated GlyRα1-dependent binding to the plasma membrane but also intracellular binding. Using a fluorescent membrane potential assay, we could identify five aptamers to be positive modulators. The positive modulation of one of the aptamers was confirmed by patch-clamp electrophysiology on L(tk) cells expressing GlyRα1 and/or GlyRα1β. This aptamer potentiated whole-cell Cl(-) currents in the presence of low concentrations of glycine. To our knowledge, this is the first demonstration ever of RNA aptamers acting as positive modulators for an ion channel. We believe that these aptamers are unique and valuable tools for further studies of GlyR biology and possibly also as tools for assay development in identifying small-molecule agonists and positive modulators.

Indexed as

AnimalsAptamers, NucleotideCell LineCell MembraneCytoplasmDrug Evaluation, PreclinicalKineticsMembrane PotentialsMicePichiaReceptors, GlycineSELEX Aptamer TechniqueSurface Plasmon ResonanceAptamers, NucleotideReceptors, Glycineaptamerfluorescent membrane potentialglycine receptorpatch-clamp electrophysiologysurface plasmon resonance

Identifiers

PMID26071243
PMCPMC4576506
OpenAlexW1549810436

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.